PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Shimizu et al. identify PLZF/ZBTB16 and its fusion proteins as pomalidomide-dependent neosubstrates of the cereblon E3 ligase. The authors also report that pomalidomide induces their degradation and thereby exerts its anti-cancer effect in leukemic cells expressing the fusion proteins.
Guardado en:
Autores principales: | Nobuyuki Shimizu, Tomoko Asatsuma-Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8e042573d7f949a6bd3a74bcd451d1ff |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
por: Sabine Beez, et al.
Publicado: (2012) -
Characterisation of genome-wide PLZF/RARA target genes.
por: Salvatore Spicuglia, et al.
Publicado: (2011) -
Crbn modulates calcium influx by regulating Orai1 during efferocytosis
por: Hyunji Moon, et al.
Publicado: (2020) -
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Mary H. Young, et al.
Publicado: (2021) -
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
por: Jian An, et al.
Publicado: (2017)